Growth Metrics

ARS Pharmaceuticals (SPRY) Amortizatization of Intangibles (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Amortizatization of Intangibles for 5 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Amortizatization of Intangibles fell 35.04% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, down 24.66% year-over-year, with the annual reading at $5.5 million for FY2025, 23.86% down from the prior year.
  • Amortizatization of Intangibles hit $1.0 million in Q4 2025 for ARS Pharmaceuticals, down from $1.1 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $5.9 million in Q2 2024 to a low of -$2.0 million in Q1 2024.
  • Historically, Amortizatization of Intangibles has averaged $262133.3 across 5 years, with a median of $285000.0 in 2021.
  • Biggest five-year swings in Amortizatization of Intangibles: plummeted 705.96% in 2023 and later soared 434.7% in 2024.
  • Year by year, Amortizatization of Intangibles stood at $243000.0 in 2021, then increased by 17.28% to $285000.0 in 2022, then crashed by 705.96% to -$1.7 million in 2023, then soared by 189.4% to $1.5 million in 2024, then crashed by 35.04% to $1.0 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for SPRY at $1.0 million in Q4 2025, $1.1 million in Q3 2025, and $1.5 million in Q4 2024.